TipRanks
TG Therapeutics (GB:0VGI)
LSE:0VGI
UK Market

TG Therapeutics (0VGI) Ratios

1 Followers

TG Therapeutics Ratios

GB:0VGI's free cash flow for Q2 2026 was $0.83. For the 2026 fiscal year, GB:0VGI's free cash flow was decreased by $ and operating cash flow was $0.09. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
4.27 4.10 6.25 5.92 3.16
Quick Ratio
3.72 3.29 5.03 5.18 3.16
Cash Ratio
1.80 0.51 1.98 1.73 1.92
Solvency Ratio
0.43 1.08 0.07 0.08 -1.65
Operating Cash Flow Ratio
0.07 -0.16 -0.45 -0.58 -3.31
Short-Term Operating Cash Flow Coverage
0.00 -23.73 0.00 0.00 0.00
Net Current Asset Value
$ 110.14M$ 215.53M$ 211.03M$ 148.86M$ 33.29M
Leverage Ratios
Debt-to-Assets Ratio
0.46 0.25 0.44 0.34 0.43
Debt-to-Equity Ratio
1.25 0.40 1.14 0.69 1.42
Debt-to-Capital Ratio
0.56 0.29 0.53 0.41 0.59
Long-Term Debt-to-Capital Ratio
0.55 0.28 0.52 0.38 0.55
Financial Leverage Ratio
2.71 1.64 2.60 2.05 3.30
Debt Service Coverage Ratio
12.64 17.07 1.98 2.04 -20.91
Interest Coverage Ratio
3.64 4.61 1.75 1.64 -21.42
Debt to Market Cap
0.09 0.06 0.06 0.04 0.04
Interest Debt Per Share
5.59 1.99 1.91 0.87 0.69
Net Debt to EBITDA
2.03 1.35 1.48 0.68 0.09
Profitability Margins
Gross Profit Margin
82.36%83.66%88.30%93.95%90.48%
EBIT Margin
16.75%21.76%15.08%10.99%-7670.41%
EBITDA Margin
16.78%21.80%15.17%11.17%-7651.92%
Operating Profit Margin
17.05%20.01%12.74%8.83%-7838.99%
Pretax Profit Margin
12.71%17.43%7.78%5.59%-8036.34%
Net Profit Margin
55.22%72.56%7.11%5.42%-8036.34%
Continuous Operations Profit Margin
55.22%72.56%7.11%5.42%-8036.34%
Net Income Per EBT
434.54%416.41%91.36%97.01%100.00%
EBT Per EBIT
74.53%87.08%61.04%63.31%102.52%
Return on Assets (ROA)
26.93%42.06%4.05%3.84%-115.62%
Return on Equity (ROE)
72.30%69.01%10.52%7.90%-382.02%
Return on Capital Employed (ROCE)
9.94%13.56%8.61%7.48%-155.53%
Return on Invested Capital (ROIC)
9.93%13.54%7.85%7.22%-153.80%
Return on Tangible Assets
26.93%42.06%4.05%3.85%-116.10%
Earnings Yield
5.97%10.39%0.53%0.52%-13.97%
Efficiency Ratios
Receivables Turnover
1.99 2.02 2.55 4.57 0.00
Payables Turnover
0.66 0.94 0.00 0.00 0.00
Inventory Turnover
0.95 0.80 0.35 0.35 0.00
Fixed Asset Turnover
112.85 98.17 46.01 29.03 0.26
Asset Turnover
0.49 0.58 0.57 0.71 0.01
Working Capital Turnover Ratio
0.90 1.29 0.89 1.23 0.01
Cash Conversion Cycle
13.20 246.53 1.19K 1.11K 0.00
Days of Sales Outstanding
183.32 181.01 143.32 79.81 0.00
Days of Inventory Outstanding
383.05 455.14 1.05K 1.03K 0.00
Days of Payables Outstanding
553.17 389.62 0.00 0.00 0.00
Operating Cycle
566.37 636.15 1.19K 1.11K 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
0.13 -0.17 -0.28 -0.22 -1.30
Free Cash Flow Per Share
0.12 -0.17 -0.28 -0.22 -1.30
CapEx Per Share
<0.01 <0.01 <0.01 0.00 <0.01
Free Cash Flow to Operating Cash Flow
0.97 1.01 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
36.41 -115.76 -900.38 0.00 -12.58K
Capital Expenditure Coverage Ratio
36.41 -115.76 -900.38 0.00 -12.58K
Operating Cash Flow Coverage Ratio
0.02 -0.10 -0.16 -0.28 -2.12
Operating Cash Flow to Sales Ratio
0.02 -0.04 -0.12 -0.13 -63.26
Free Cash Flow Yield
0.22%-0.58%-0.93%-1.30%-11.00%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
17.14 9.62 188.13 191.33 -7.16
Price-to-Sales (P/S) Ratio
9.99 6.98 13.29 10.38 575.19
Price-to-Book (P/B) Ratio
12.25 6.64 19.67 15.11 27.34
Price-to-Free Cash Flow (P/FCF) Ratio
459.56 -172.18 -107.84 -77.18 -9.09
Price-to-Operating Cash Flow Ratio
413.91 -173.67 -107.96 -77.18 -9.09
Price-to-Earnings Growth (PEG) Ratio
0.03 <0.01 2.38 -1.80 0.16
Enterprise Value Multiple
61.57 33.37 89.13 93.58 -7.43
Enterprise Value
8.26B 4.48B 4.45B 2.44B 1.58B
EV to EBITDA
61.57 33.37 89.13 93.58 -7.43
EV to Sales
10.33 7.28 13.52 10.45 568.28
EV to Free Cash Flow
475.20 -179.45 -109.66 -77.75 -8.98
EV to Operating Cash Flow
462.14 -181.00 -109.78 -77.75 -8.98
Tangible Book Value Per Share
4.26 4.49 1.53 1.13 0.43
Shareholders’ Equity Per Share
4.26 4.49 1.53 1.13 0.43
Tax and Other Ratios
Effective Tax Rate
-3.35 -3.16 0.09 0.03 0.00
Revenue Per Share
5.64 4.27 2.26 1.65 0.02
Net Income Per Share
3.11 3.10 0.16 0.09 -1.65
Tax Burden
4.35 4.16 0.91 0.97 1.00
Interest Burden
0.76 0.80 0.52 0.51 1.05
Research & Development to Revenue
0.28 0.26 0.29 0.33 45.01
SG&A to Revenue
0.37 0.38 0.47 0.53 34.29
Stock-Based Compensation to Revenue
0.10 0.10 0.13 0.16 6.89
Income Quality
0.04 -0.06 -1.73 -2.48 0.89
Currency in USD